For instance, in Alzheimer’s disease models, inhibition of CDK5 alleviate cognitive defects.476 Novel approaches, such as specific protein degraders, or computationally designed small-molecule inhibitors, could help determine whether targeting CDK5 could delay or prevent the progression of such invalidating disease, without causing significant toxicity. Here, CDK5 is linked to early-onset autosomal dominant Alzheimer disease.